🟢PT-141 | 10 mg

PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It has gained attention for its use in treating sexual dysfunction, specifically hypoactive sexual desire disorder (HSDD) in premenopausal women and erectile dysfunction (ED) in men. Unlike traditional treatments, PT-141 works by activating melanocortin receptors, particularly the melanocortin 4 receptor (MC4R), which are crucial in regulating sexual arousal.

MC4R is a G-protein-coupled receptor (GPCR) found in the central nervous system, and its activation by PT-141 triggers intracellular signaling pathways, including the cAMP pathway, leading to increased neuronal activity in brain regions associated with sexual arousal. This mechanism of action is distinct from other treatments that focus on the vascular system, offering a central approach to managing sexual desire and arousal.

Clinical trials have shown that PT-141 is effective in increasing sexual desire and reducing distress in premenopausal women with HSDD. The FDA approved Bremelanotide for this indication in 2019. Additionally, studies have demonstrated its efficacy in improving erectile function in men, particularly those unresponsive to traditional PDE5 inhibitors like sildenafil (Viagra). The safety profile of PT-141 has been considered favorable, further supporting its use as a valuable option for patients with HSDD and ED. PT-141’s unique approach, targeting central nervous system pathways, provides a promising alternative for individuals who may not respond to existing treatments.